Sep 7, 2008 7:16 AM ET | Site Changes | Help
Results 1 - 10 of 39 : 1 2 3 4 Next
The pharmaceutical makes an all-in bet on an unproven market.
Flamel Tries to Get It in Gear
The biopharma has irons in the fire, but will they ignite a turnaround?
The activist investor officially launches his bid to usurp Biogen's board of directors.
The drugmaker searches for partners as a label expansion moves forward.
New sales data arrives for one lead drug, new data for another.
The pharmaceutical's hit with a baseless, regrettably common type of lawsuit.
Headache Over for Pozen and Glaxo?
The duo's FDA headache is over, but a new one is about to begin.
After a choppy year, the drugmaker says there are plenty of new possibilities in its pipeline.
This Just In: Upgrades and Downgrades
Rodman & Renshaw on Genentech: The patient will live.
No Fire Fueling Flamel's Top Drug
Coreg's latest sales numbers sputter.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK